Replies to post #124740 on Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

I believe that Dickie Vogel and Josh Scheinfeld may have either curtailed or capped this agreement, as there has been little/no activity shown on LPC in recent filings that I am aware of, other than below:

http://www.marketwatch.com/story/10-k-amarantus-bioscience-holdings-inc-2015-04-06

Lincoln Park Capital

In March 2014, we entered into an agreement with Lincoln Park Capital Fund LLC ("LPC") for an equity financing agreement. LPC is obligated to purchase up to $20,000,000 of the Company's common stock from time to time over a 30 month period, in amounts up to $500,000 per sale as directed by the Company and subject to certain requirements, restrictions and limitations. There are no upper limits to the price LPC may pay to purchase our common stock and the purchase price is based on prevailing market prices of our stock at the time of sales without any fixed discount, We control the timing and amount of any sales to LPC In addition, we may direct LPC to purchase additional amounts as accelerated purchases the closing price of our stock is not below certain threshold price. We filed a registration statement with the SEC covering the shares issuable to LPC. As of December 31, 3104, we had approximately $17,300,000 available to us under the agreement. Through March 25, 2015, the Company has sold an additional 37,445,801 shares of common stock for gross proceeds of $2,767,000 under its agreement with LPC.

Dickie and Josh came to AMBS through an intro by me, and financial modeling of Elite Pharma (ELTP).

AJMHO